Joseph TT, Bu W, Lin W, Zoubak L, Yeliseev A, Liu R et al (2021) Ketamine metabolite (2R,6R)-Hydroxynorketamine interacts with µ and κ opioid receptors. ACS Chem Neurosci 12(9):1487–1497

Article  CAS  PubMed  Google Scholar 

Dezfulian C, Orkin AM, Maron BA, Elmer J, Girotra S, Gladwin MT et al (2021) Opioid-Associated out-of-hospital cardiac arrest: distinctive clinical features and Implications for Health Care and public responses: A Scientific Statement from the American Heart Association. Circulation 143(16):e836–e70

Article  PubMed  Google Scholar 

Bell J, Strang J (2020) Medication treatment of opioid Use Disorder. Biol Psychiatry 87(1):82–88

Article  CAS  PubMed  Google Scholar 

Rasmussen K, White DA, Acri JB (2019) NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology 44(4):657–659

Article  PubMed  Google Scholar 

Wilson N, Kariisa M, Seth P, Smith Ht, Davis NL (2020) Drug and opioid-involved overdose deaths - United States, 2017–2018. MMWR Morb Mortal Wkly Rep 69(11):290–297

Article  PubMed  PubMed Central  Google Scholar 

Volkow ND, Collins FS (2017) The role of Science in addressing the Opioid Crisis. N Engl J Med 377(4):391–394

Article  PubMed  Google Scholar 

Jones G, Ricard JA, Lipson J, Nock MK (2022) Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep. 12(1)

Parker LA, Siegel S, Luxton T (1995) Ibogaine attenuates morphine-induced conditioned place preference. Exp Clin Psychopharmacol 3:344–348

Article  CAS  Google Scholar 

Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr. et al (1994) Effects of Iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 657(1–2):14–22

Article  CAS  PubMed  Google Scholar 

Francés B, Gout R, Cros J, Zajac JM (1992) Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam Clin Pharmacol 6(8–9):327–332

Article  PubMed  Google Scholar 

Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S et al (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psychiatry 14:1183740

Article  PubMed  PubMed Central  Google Scholar 

Lavaud C, Massiot G (2017) The Iboga alkaloids. Prog Chem Org Nat Prod 105:89–136

CAS  PubMed  Google Scholar 

Mendes FR, Costa CS, Wiltenburg VD, Morales-Lima G, Fernandes JAB, Filev R (2022) Classic and non-classic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci 3:100025

Article  Google Scholar 

Kelmendi B, Kaye AP, Pittenger C, Kwan AC (2022) Psychedelics Curr Biol 32(2):R63–r7

Article  CAS  PubMed  Google Scholar 

Aleksandrova LR, Phillips AG (2021) Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci 42(11):929–942

Article  CAS  PubMed  Google Scholar 

Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G et al (2023) The Bright side of Psychedelics: latest advances and challenges in Neuropharmacology. Int J Mol Sci. 24(2)

Perez LG, Siconolfi D, Troxel WM, Tucker JS, Seelam R, Rodriguez A et al (2022) Loneliness and multiple health domains: associations among emerging adults. J Behav Med 45(2):260–271

Article  PubMed  PubMed Central  Google Scholar 

Maguire DR (2023) Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus monkeys. J Pharmacol Exp Ther 384(1):155–162

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weleff J, Pulido-Saavedra A, Anand A, Nero N, Nia AB (2023) CRD42023392307 Angarita. GA. The therapeutic effects of psychedelics for opioid use disorder: a systematic review of clinical studies. PROSPERO 2024

Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW et al (2023) Clinical Trial Design challenges and opportunities for emerging treatments for opioid use disorder: a review. JAMA Psychiatry 80(1):84–92

Article  PubMed  PubMed Central  Google Scholar 

Volkow ND, Gordon JA, Wargo EM (2023) Psychedelics as therapeutics-potential and challenges. JAMA Psychiatry 80(10):979–980

Article  PubMed  Google Scholar 

(CDER) Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry DRAFT GUIDANCE www.fda.gov2023 updated 06/26/2023; cited 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

Rodrigues LS, Rossi GN, Rocha JM, F LO, Bouso JC, Hallak JEC et al (2022) Effects of Ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci 272(4):541–556

Article  PubMed  Google Scholar 

Hilal FF, Jeanblanc J, Deschamps C, Naassila M, Pierrefiche O, Ben Hamida S (2024) Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies. J Neural Transm (Vienna) 131(5):525–561

Article  PubMed  Google Scholar 

Mertens LJ, Preller KH (2021) Classical psychedelics as therapeutics in Psychiatry - Current Clinical evidence and potential therapeutic mechanisms in Substance Use and Mood disorders. Pharmacopsychiatry 54(4):176–190

Article  PubMed  Google Scholar 

Hornick MG, Stefanski A (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Front Pharmacol 14:1221719

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L et al (2020) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synthesis 18(10):2119–2126

Article  Google Scholar 

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D et al (2018) PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169(7):467–473

Article  PubMed  Google Scholar 

Saavedra AP, Oliva HNP, Kitaneh R, Funaro MC, Angarita GA (2023) Effects of Psychedelics on opioid use disorder. Protocol for a Scoping Review of Preclinical Studies

Leenaars M, Hooijmans CR, van Veggel N, ter Riet G, Leeflang M, Hooft L et al (2012) A step-by-step guide to systematically identify all relevant animal studies. Lab Anim 46(1):24–31

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C (2016) PRESS peer review of electronic search strategies: 2015 Guideline Statement. J Clin Epidemiol 75:40–46

Article  PubMed  Google Scholar 

Nichols DE, Psychedelics (2016) Pharmacol Rev 68(2):264–355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol 14(1):43

Article  PubMed  PubMed Central  Google Scholar 

MapChart (2024) Available from: https://www.mapchart.net/about.html

Brent PJ, Chahl LA (1993) Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur Neuropsychopharmacol 3(1):23–32

Article  CAS  PubMed  Google Scholar 

Dzoljic ED, Kaplan CD, Dzoljic MR (1988) Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch Int Pharmacodyn Ther 294:64–70

CAS  PubMed  Google Scholar 

Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991) Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 195(3):341–345

Article  CAS  PubMed  Google Scholar 

Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN (1992) Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 31(5):497–500